The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Clinical and Genetic Associations in Cephalosporin‐Induced Liver Injury: Insights From the Drug‐Induced Liver Injury Network
Abstract
Introduction: Cephalosporins are widely prescribed antibiotics due to their efficacy and safety. Although rare, idiosyncratic drug‐induced liver injury (DILI) has been reported with their use. Here, we characterise the clinical features and HLA associations of cephalosporin‐related liver injury. Methods: Between Jan 1, 2004, and Nov 2, 2022, a total of 2347 cases of DILI were enrolled in the DILIN study, of which 1854 were adjudicated as probable, highly likely, or definite. HLA sequencing was performed, and association with the risk of DILI was examined. Results: 58 cases (3%) were attributed to different cephalosporins, including cefazolin ( n = 40), cephalexin ( n = 4), ceftriaxone ( n = 3), cefdinir ( n = 3), cefuroxime ( n = 3), and five other individual agents. Clinical features included a self‐limited course with a mixed or cholestatic biochemical pattern without hypersensitivity features occuring in 1 to 4 weeks. Most striking was the phenotype of cefazolin and other parenteral cephalosporins given as a single dose with the onset of jaundice, fatigue, and itching 1 to 3 weeks later. In the total cohort, HLA‐A*02:01 was significantly associated with an increased risk of cephalosporin‐induced liver injury (OR: ~2.5–2.7, P < 0.0001). The association was strongest with cefazolin, with carrier frequencies of 85% vs. 38% in those with DILI from other drugs. Conclusions: Cephalosporins can cause self‐limited, mixed/cholestatic hepatitis that arises after a short course of therapy with a latency of up to 3 weeks with cefazolin. Cephalosporin‐induced liver injury is associated with the HLA‐A*02:01 allele, which is linked to more severe liver injury at the onset of illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HLA polymorphisms shown to be significantly associated with multiple drugs include HLA-A*02:01 for AC and cefazolin DILI and HLA-B*35:01 for multiple HDS products, including green tea extract, turmeric, and Polygonum multiform.”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [30]
In the citing paper
“Several polymorphisms in human leukocyte antigen (HLA) class I and II alleles have been associated with drug-specific idiosyncratic DILI (Table 3).29–37”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
The positive false discovery rate: a Bayesian interpretation and the q-value
Storey, J. D. (2003) · The Annals of Statistics · doi:10.1214/aos/1074290335 · Cited by 2,204
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
study, F. T. D., Daly, A. K., International SAE Consortium, Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.379 · Cited by 944
Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study
Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K. R., Watkins, P. B., Navarro, V., Barnhart, H., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.006 · Cited by 925
Self-citationANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755
Self-citationDrug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Self-citationThe Use of Cephalosporins in Penicillin-allergic Patients: A Literature Review
Campagna, J. D., Bond, M. C., Schabelman, E., & Hayes, B. D. (2012) · The Journal of Emergency Medicine · doi:10.1016/j.jemermed.2011.05.035 · Cited by 243
Cephalosporins as key lead generation beta-lactam antibiotics
Lin, X., & Kück, U. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12272-8 · Cited by 166
A missense variant in PTPN22 is a risk factor for drug-induced liver injury
Cirulli, E. T., Nicoletti, P., Abramson, K., Andrade, R. J., Bjornsson, E. S., Chalasani, N., Fontana, R. J., Hallberg, P., Li, Y. J., Lucena, M. I., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.034 · Cited by 137
Self-citationPichler, W. J., Adam, J., Watkins, S., Wuillemin, N., Yun, J. J., & Yerly, D. (2015) · International Archives of Allergy and Immunology · doi:10.1159/000441280 · Cited by 92
Li, Y., Phillips, E. J., Dellinger, A., Nicoletti, P., Schutte, R., Li, D., Ostrov, D. A., Fontana, R. J., Watkins, P. B., Stolz, A., et al. (2021) · Hepatology · doi:10.1002/hep.31258 · Cited by 76
Self-citationIdentification and Characterization of Cefazolin-Induced Liver Injury
Alqahtani, S. A., Kleiner, D. E., Ghabril, M., Gu, J., Hoofnagle, J. H., & Rockey, D. C. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.036 · Cited by 61
Self-citationChalasani, N., Li, Y., Dellinger, A. E., Navarro, V. J., Bonkovsky, H. L., Fontana, R. J., Gu, J., Barnhart, H. X., Phillips, E., Lammert, C. S., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.010 · Cited by 50
Self-citationNicoletti, P., Dellinger, A., Li, Y. J., Barnhart, H. X., Chalasani, N., Fontana, R. J., Odin, J. A., Serrano, J., Stolz, A., Etheridge, A. S., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.11.036 · Cited by 50
Self-citationDrug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Bonkovsky, H. L., Watkins, P. B., Serrano, J., Davern, T. J., Chalasani, N., Rochon, J., & Fontana, R. J. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/yrfh-p349 · Cited by 45
Self-citationRecommendations for pharmacogenetic testing in clinical practice guidelines in the US
Hertz, D. L., Bousman, C., McLeod, H. L., Monte, A. A., Voora, D., Orlando, L. A., Crutchley, R. D., Brown, B. R. B., Teeple, W., Rogers, S. L., et al. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae110 · Cited by 39
Kang, Y., Kim, S., Park, S., Park, B. Y., Lee, J., An, J. Y., Won, H., Song, W., Kwon, H., Cho, Y. S., et al. (2020) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2020.12.3.430 · Cited by 38
Vancomycin-Induced Liver Injury, DRESS, and HLA-A∗32:01
Asif, B. A., Koh, C., Phillips, E. J., Gu, J., Li, Y., Barnhart, H. X., Chalasani, N., Fontana, R. J., Hayashi, P. H., Navarro, V. J., et al. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.09.011 · Cited by 34
Self-citationEstimated Exposure to 6 Potentially Hepatotoxic Botanicals in US Adults
Likhitsup, A., Chen, V. L., & Fontana, R. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.25822 · Cited by 30
Self-citationBessone, F., Hernandez, N., Medina-Caliz, I., García-Cortés, M., Schinoni, M. I., Mendizabal, M., Chiodi, D., Nunes, V., Ridruejo, E., Pazos, X., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.06.030 · Cited by 24
Management of Penicillin Allergy in the Perioperative Setting
Sexton, M. E., & Kuruvilla, M. E. (2024) · Antibiotics · doi:10.3390/antibiotics13020157 · Cited by 22
Incidence of Idiosyncratic Drug-Induced Liver Injury Caused by Prescription Drugs
Chen, V. L., Rockey, D. C., Bjornsson, E. S., Barnhart, H., Hoofnagle, J. H., & for the Drug-Induced Liver Injury Network Investigators (2025) · Drug Safety · doi:10.1007/s40264-024-01486-6 · Cited by 15
Self-citationGenotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact Analysis
Manson, L. E. N., van den Hout, W. B., & Guchelaar, H. (2021) · Pharmaceuticals · doi:10.3390/ph15010004 · Cited by 14
The Frequency of Drug-Induced Liver Injury Due to Antibiotics Among Hospitalised Patients
Björnsson, R. A., Sigurdsson, S. S., Arnarson, D. T., Logason, E., & Björnsson, E. S. (2025) · Drug Safety · doi:10.1007/s40264-025-01541-w · Cited by 12
Line, J., Ali, S.-E., Grice, S., Rao, T., & Naisbitt, D. J. (2023) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.3c00253 · Cited by 10
Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database
Barritt, A. S., Hayashi, P. H., Stolz, A., Barnhart, H. X., Hoofnagle, J. H., & for the Drug-Induced Liver Injury Network (DILIN) (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003145 · Cited by 9
Self-citationWallner, J. J., Beck, I. A., Panpradist, N., Ruth, P. S., Valenzuela-Ponce, H., Soto-Nava, M., Ávila-Ríos, S., Lutz, B. R., & Frenkel, L. M. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0103 · Cited by 6
Research works printed but not linked: 3
- Bui T., 2024, StatPearls
- 2012, LiverTox: Clinical and Research Information on Drug‐Induced Liver Injury
- Gilani B., 2024, HLA B 5701 Testing
Cited by
The contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
Self-citation
Metadata
- Authors
- Vuppalanchi, R., Li, Y., Rockey, D. C., Halegoua‐DeMarzio, D., Fontana, R. J., Bonkovsky, H. L., Koh, C., Odin, J., Barnhart, H., Hoofnagle, J. H., & Drug‐Induced Liver Injury Network (DILIN)
- Affiliations
- Indiana University School of Medicine Indianapolis Indiana USA
- Duke University School of Medicine Durham North Carolina USA
- Medical University of South Carolina Charleston South Carolina USA
- Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia Pennsylvania USA
- University of Michigan Ann Arbor Michigan USA
- Atrium Health Wake Forest Baptist and Wake Forest University School of Medicine Winston‐Salem North Carolina USA
- National Institute of Diabetes and Digestive and Kidney Diseases Bethesda Maryland USA
- Icahn School of Medicine at Mount Sinai New York New York USA
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2025-07-20
- Volume
- 62
- Issue
- 10
- Pages
- 1012-1022
- ISSN
- 0269-2813
- 1365-2036
- PMC
- PMC12543336
- Cited by
- 10
- References
- 29
- Language
- en
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK065211, U01DK065184, U01DK065201, U01DK083020, U01DK083027, U24DK065176)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.